Search Results
Your search for ,ouT matches 5632 pages
Showing 1601 - 1650ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma
In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Axicabtagene ciloleucel has improved ...
Expert Point of View: John C. Krauss, MD
The invited discussant of the GARNET study, John C. Krauss, MD, Medical Oncology Director of the Multidisciplinary Colorectal Cancer Clinic, Rogel Cancer Center of the University of Michigan, Ann Arbor, observed that “impressive” response rates to dostarlimab were demonstrated in a “relatively...
Expert Point of View: Michael J. Overman, MD
The study’s invited discussant, Michael J. Overman, MD, Professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, said the findings of the study presented by Henriksen et al1 add to a convincing body of data showing that “the use of circulating...
Expert Point of View: Rachna T. Shroff, MD
Invited discussant of the ClarIDHy trial, Rachna T. Shroff, MD, Associate Professor of Medicine, University of Arizona, and Chief of GI Medical Oncology at the University of Arizona Cancer Center, said positive findings for ivosidenib support the notion that “biliary cancer is a perfect example of...
I Credit Cancer Research With Saving My Life
In December 2015, I thought I was through with cancer. I was diagnosed with prostate cancer in 2011 after a routine blood test showed that my prostate-specific antigen (PSA) level was high. I underwent prostatectomy, and although it was clear the cancer had breached the capsule of the prostate, for ...
Looking Back on the 40-Year Career of Richard L. Schilsky, MD, FACP, FSCT, FASCO
The medical career of Richard L. Schilsky, MD, FACP, FSCT, FASCO, spans more than 4 decades and includes a roster of nearly unprecedented accomplishments in patient care, research, and mentoring. He has held leadership positions in academia, first at the University of Chicago, where he spent the...
NCCN Shares New Recommendations for Vaccinating Patients With Cancer Against COVID-19
The National ComprehensiveCancer Network® (NCCN) has released new guidance1 on vaccinating people with cancer against COVID-19. The nonprofit alliance of leading cancer centers created an NCCN COVID-19 Vaccine Committee, which includes hematology and oncology experts with particular expertise in...
MURANO Trial: Venetoclax Plus Rituximab Achieves Durable Progression-Free Survival in Resistant CLL
Patients with relapsed or refractory chronic lymphocytic leukemia (CLL) treated with the combination of fixed-duration venetoclax/rituximab had a longer overall survival and progression-free survival at 5 years compared with those treated with bendamustine/rituximab, according to a 5-year analysis...
LCMC3 Trial: Neoadjuvant Atezolizumab for Patients With Stage IB to IIIB Resectable Lung Cancer
Neoadjuvant treatment with single-agent atezolizumab for patients with stage IB to IIIB lung cancer resulted in a major pathologic response rate of 21% and pathologic complete response rate of 7% in the primary analysis of the Lung Cancer Mutation Consortium 3 (LCMC3) study. The findings were...
Emil J Freireich, MD, Dies at 93
Emil J Freireich, MD, an oncologist who developed groundbreaking therapies for childhood leukemia and came to be recognized as a founding father of modern clinical cancer research, passed away on February 1. He was 93. Dr. Freireich was a faculty member at The University of Texas MD Anderson Cancer ...
Early Research Explores Relationship Between CD58 Loss and Resistance to CAR T-Cell Therapies
Engineering chimeric antigen receptor (CAR) T cells to overcome CD58 loss may be a way to boost responses in patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to treatment with axicabtagene ciloleucel and other CAR T-cell therapies, according to an experimental study presented...
Patients in Cancer Remission Also at Higher Risk for Severe COVID-19 Illness
Patients with inactive cancer who are not currently undergoing treatment also face a significantly higher risk of severe illness from COVID-19, according to a new study published by Sun et al in JNCI Cancer Spectrum. The findings underscore the importance of COVID-19 mitigation, like social...
Study Identifies Four Unique Subtypes of Small Cell Lung Cancer
Researchers have developed the first comprehensive framework to classify small cell lung cancer (SCLC) into four unique subtypes based on gene expression and have identified potential therapeutic targets for each type. These findings were published by Gay et al in Cancer Cell. SCLC is known for...
It All Began With a Lump in the Throat
BOOKMARK Title: Milkshakes and Morphine: A Memoir of Love and LifeAuthor: Genevieve FoxPublisher: VintagePublication date: January 2019Price: $15.95, paperback, 384 pages “It doesn’t hurt, but I know it is there and I know it shouldn’t be. Interloper. I have touched it a couple of times already,...
CDC Awards Huntsman Cancer Institute $3 Million to Improve Colorectal Cancer Screening
Huntsman Cancer Institute (HCI) at the University of Utah has been awarded a 5-year, $3 million grant from the Centers for Disease Control and Prevention (CDC) to improve Utah’s colorectal cancer screening rates. The program will build on an ongoing partnership between HCI’s Center for Health...
Significant Survival Benefit From Chemotherapy for Older Women With Triple-Negative Breast Cancer
Women older than age 70 diagnosed with triple-negative breast cancer had significantly improved overall survival if they received adjuvant and/or neoadjuvant chemotherapy, according to an analysis of data from more than 16,000 women enrolled in the National Cancer Database. The estimated 5-year...
Expert Point of View: Sagar Lonial, MD, and Adam D. Cohen, MD
The studies of ALLO-715 “off-the-shelf” CAR T-cell therapy and bb21217 impressed two experts in the field. Sagar Lonial, MD, the Anne and Bernard Gray Family Chair in Cancer, Chair and Professor of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, and Adam D. Cohen, MD, ...
Novel Anti-BCMA CAR T-Cell Therapies Show Activity in Myeloma
In the treatment of relapsed or refractory multiple myeloma, chimeric antigen receptor (CAR) T-cell therapies with unique characteristics, still targeting B-cell maturation antigen (BCMA), are looking promising. At the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition,...
Expert Point of View: Suzanne Lentzsch, MD, PhD
IFM 2009 showed that autologous stem cell transplant (ASCT) combined with lenalidomide, bortezomib, and dexamethasone (RVd) results in a significantly better progression-free survival than RVd alone in newly diagnosed patients with myeloma.1 “The data favor immediate ASCT, as transplant resulted in ...
Expert Point of View: Yuan Yuan, MD, PhD, and Elizabeth Mittendorf, MD, PhD
Yuan Yuan, MD, PhD, a medical oncologist at City of Hope, Duarte, California, weighed in on the KEYNOTE-355 findings. “The study presented by Dr. Rugo on KEYNOTE-355 reconfirms the utility of adding immune checkpoint inhibitorsto chemotherapy as front-line treatment for metastatic triple-negative...
ASCO’s New Chief Medical Officer Plans to Tackle the Global Burden of Cancer and Disparities in Access to Care
In November, ASCO announced that Julie R. Gralow, MD, FACP, FASCO, will succeed Richard L. Schilsky, MD, FACP, FSCT, FASCO, as Chief Medical Officer (CMO) of the Society. Dr. Gralow will begin her new position on February 15, 2021. Dr. Gralow’s long relationship with ASCO dates back to 1995, when...
Expert Point of View: Cristina Saura Manich, MD, PhD
Study discussant Cristina Saura Manich, MD, PhD, Head of the Breast Cancer Program at the Vall d’Hebron University Hospital in Barcelona, offered some thoughts as to the underlying mechanism of benefit from trilaciclib in the phase II study reported by Dr. Joyce A. O’Shaugnessy. Trilaciclib is a...
Gastrointestinal Oncologist Laura Goff, MD, Sees Potential in Emerging Immunotherapies and Novel Targeted Agents
Laura Goff, MD, Medical Director of the Hematology and Oncology Division at Vanderbilt-Ingram Cancer Center, Nashville, was born in Chicago but reared in Lewisville, a suburb of Dallas. “I come from a long line of nurses, which early on influenced my decision to pursue a career in medicine....
NCCN Shares New Recommendations for Vaccinating Patients With Cancer Against COVID-19
The National Comprehensive Cancer Network® (NCCN) has released new guidance on vaccinating people with cancer against COVID-19. The nonprofit alliance of leading cancer centers created an NCCN COVID-19 Vaccine Committee that includes hematology and oncology experts with particular expertise in...
ASCO Statement on ‘Cancer Statistics, 2021’
ASCO’s Chief Medical Officer and Executive Vice President Richard L. Schilsky, MD, FACP, FSCT, FASCO, issued the following statement on “Cancer Statistics, 2021,” a report published annually by the American Cancer Society. “Fifty years after President Nixon signed the National Cancer Act to make...
Are Some Oral Pathogens More Common in Patients With Esophageal Cancer?
In a new study published by Kawasaki et al in the journal Cancer, researchers reported that certain oral pathogens are more prevalent in patients with esophageal cancer, and pointed out this information may be used as a novel diagnostic tool. The oral cavity is a rich source of microbial diversity, ...
Dense Breast Notification Legislation: Recorded Effects and Future Recommendations
According to findings published by Kressin et al in the Journal of the American College of Radiology, women living in states where dense breast notifications are legislatively mandated had higher rates of being informed about personal breast density and of having had breast density discussions with ...
Empowering the FDA to Require Dose Optimization of All New Oncology Drugs
The vast majority of drugs used outside of oncology are evaluated in randomized dose-ranging trials to optimize the therapeutic index prior to the pivotal phase III trial. No one would think of dosing a statin or an antibiotic at the highest dose patients could tolerate, especially if that dose...
Single-Institution Study Finds Decrease in Cancer Screenings, Diagnoses During the First Wave of the COVID-19 Pandemic
Researchers have documented a substantial decline in cancer and precancer diagnoses at the Northeast's largest health-care system (Massachusetts General Brigham) during the first peak of the COVID-19 pandemic due to a drop in the number of cancer screening tests performed. These findings were...
Performing Mammograms for Targeted Hospitalized Patients
Completing cancer screening tests such as mammograms can be challenging for low-income patients who may face such issues as lack of transportation or inability to take time off work. A team at Massachusetts General Hospital explored the possibility of addressing preventive care needs when patients...
COA Submits Letter to Governors, Public Health Officials to Request Independent Oncology Practices Be Given Priority Approval to Administer COVID-19 Vaccines
Today, leadership from the Community Oncology Alliance (COA) sent a letter urging the nation's governors and public health officials to prioritize supplying cancer treatment practices with COVID-19 vaccines and allowing the practices to administer the vaccines. The letter, signed by Kashyap Patel,...
Can Postoperative Whole-Breast Irradiation Be Safely Omitted in Older Women With Low-Risk Breast Cancer?
Omitting postoperative radiotherapy with whole-breast irradiation may not compromise 10-year overall survival or increase the risk of developing metastasis in most women 65 years and older with low-risk breast cancer, according to results of the large randomized PRIME II trial reported at the 2020...
Record Drop in Cancer Mortality for Second Straight Year Due to Improved Lung Cancer Treatment Reported in ‘Cancer Statistics, 2021’
Overall cancer death rates in the United States dropped continuously from 1991 through 2018, for a total decrease of 31%, including a 2.4% decline from 2017 to 2018. These findings were reported in the American Cancer Society’s “Cancer Statistics, 2021” article, published by Rebecca L. Siegel, MPH, ...
Expert Point of View: Sagar Lonial, MD
Sagar Lonial, MD, the Anne and Bernard Gray Family Chair in Cancer, Chair and Professor of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, commented on the APOLLO trial for The ASCO Post. “APOLLO is a highly awaited study, as the use of daratumumab plus...
Feasibility Study of Radical Cystectomy vs Intravesical BCG for High-Grade, Non–Muscle Invasive Bladder Cancer
As reported in the Journal of Clinical Oncology by Catto et al, the BRAVO-Feasibility study showed that recruitment of patients with high-grade, non–muscle invasive bladder cancer into a randomized trial comparing radical cystectomy vs intravesical bacillus Calmette-Guérin (BCG) proved difficult,...
Global Burden of Cervical Cancer and Association With HIV
A research team has quantified the effects of infection with the human immunodeficiency virus (HIV) on the development of cervical cancer. Their results show that the risk of developing cervical cancer is six times higher in women who are infected with HIV, and that women who live in Southern and...
American Cancer Society Report Identifies Critical Gaps and Research Opportunities for Improved Cancer Care
A new report found that despite progress in the decline of cancer mortality, there are still critical gaps, including the need to develop better tools and explore research opportunities that would lead to limiting cancer as a major health concern. This blueprint article completes an eight-part...
Reducing Disparities in Cancer Care for Sexual and Gender Minority Patients
Although efforts have been made by various medical societies, including ASCO, over the past decade to address the needs of sexual and gender minorities in the cancer care setting, research shows that lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) patients continue to face...
Effect of the COVID-19 Pandemic on Lung Cancer Screening
Reporting on how deferred care worsened outcomes for patients with lung cancer when the COVID-19 pandemic first surged in the spring of 2020, Robert M. Van Haren, MD, MSPH, FACS, and colleagues explained that they have identified a framework that could help people with serious health conditions...
Anthony Fauci, MD, Encourages Patients With Cancer to Receive COVID-19 Vaccine
The American Society of Hematology (ASH) President Stephanie Lee, MD, MPH, sat down with Anthony Fauci, MD, Director of the National Institutes of Allergy and Infectious Diseases (NIAID) and medical advisor to President-Elect Joseph Biden, for a virtual fireside chat about COVID-19 and cancer at...
Study Reports Highly Skilled Surgeons Significantly Reduce Death From Colon Cancer
To improve long-term survival odds, individuals with early-stage colon cancer should have their surgery performed by highly skilled surgeons. In a study that used video assessment, surgeons with highly ranked skills gave their patients a 69% lower risk of dying at 5 years as compared with their...
Chronicling a Family’s History of Cancer
Cancer has been an intimate part of Nancy Borowick’s life since her mother, Laurel, was diagnosed with breast cancer in 1997, when Nancy was 12. She began photographing her mother’s journey with the disease after the cancer recurred in 2009 for her final project for the Documentary Photography and ...
City of Hope Physician Joins Carol Emmott Fellowship
Lorna Rodriguez-Rodriguez, MD, PhD, Vice Chair of Faculty Development at City of Hope, is among 21 women leaders in the nation who were invited to join the Carol Emmott Fellowship Class of 2021, a 14-month program for “exceptional, innovative women leaders who are making lasting change in their...
ASH Recognizes Choosing Wisely Champions at Annual Meeting & Exposition
The American Society of Hematology (ASH) recognized three Choosing Wisely Champions, practitioners working to tackle overuse of hematology tests and treatments, at the all-virtual 2020 ASH Annual Meeting & Exposition. Choosing Wisely, a program of the ABIM Foundation and Consumer Reports, aims...
European Experts Tackle HPV-Related Cancers
The prevention of infection with the human papillomavirus (HPV), and its related cancers, has become a focus of the European Cancer Organisation. At the group’s 2020 European Cancer Summit, held virtually, members of the organization’s HPV Action Network convened with other experts to share...
Panel on Global Cancer Control Looks for Ways Forward in a War That’s Proving Hard to Win
Are we winning the war on cancer? It’s not so clear, especially with COVID-19 poised to erase recent gains, panelists said at a session on global cancer control at the 2020 European Cancer Summit, which was sponsored by the European Cancer Organisation. “We know what we have to do. My question is...
Addressing Inequality in Cancer Care on a Global Scale
It has become a familiar theme of late: Inequities exist in all aspects of cancer care. Although study after study documents problems with access to care and poorer cancer outcomes among underrepresented groups, less is heard about organized efforts to address these issues. This critical topic was...
IU Simon Researcher Receives $1.3 Million Grant to Improve Breast Cancer Treatment for Black Women
Harikrishna Nakshatri, PhD, who is identifying the unique biology that may make Black women more susceptible to aggressive breast cancer, received a $1.3 million grant from the Department of Defense–Congressionally Directed Medical Research Program’s breast cancer research program. Dr. -Nakshatri...
Intratumoral Injections May Boost Neoadjuvant Response in Resectable Melanoma
Studies reported at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting, which was held virtually, showed promise for the use of intratumoral injections of novel immunotherapies in treating advanced, resectable melanoma. In the 3-year interim analysis of a global phase II randomized...
Expert Point of View: Omid Hamid, MD
Omid Hamid, MD, Chief of Research/Immuno-Oncology at The Angeles Clinic & Research Institute and Co-Director of the Cutaneous Malignancy Program at Cedars-Sinai Cancer Center, Los Angeles, commented on the investigational use of bempegaldesleukin in melanoma. “The role of interleukin-2 [Il-2]...
